Ripivirin API

Name	Ripivirin
Chinese name	利匹韦林
Cas Number	500287-72-9
Source	India
Qualifications	USDMF/-/-/-/-

Rilpivirin, the original research company is Johnson & Johnson, was approved by the US FDA on May 20, 2011. It is a second-generation non-nucleoside reverse transcriptase inhibitor, compared with other commercial non-nucleoside reverse transcriptase inhibitors Has a longer half-life and better side effects characteristics. Rilpivirin binds non-competitively in the allosteric hydrophobic binding pocket away from the active site of HIV reverse transcriptase, and the combined complex interferes with the activity of reverse transcriptase, thereby achieving the purpose of inhibiting virus replication. A large number of clinical studies have shown that rilpivirin is highly active against wild-type and mutant virus strains, and the incidence of adverse reactions caused by rilpivirin treatment is lower than that of efavirenz. Rilpivirin has the advantages of small dose, high antiviral activity and resistance to drug resistance, good tolerance and safety, and less drug interactions. In addition, some studies have found that rilpivirin may have beneficial effects on chronic liver diseases, and relevant research results are expected to help develop new therapies for the treatment of liver diseases. In 2019, global sales of ripivarin were 5.93 billion yuan.

Hot Tags: ripivirin api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Salmeterol Xinafoate API, Tavaborol API, Rasagiline Mesylate API, Temozolomide API, Lurasidone Hydrochloride API, Vardenafil API

• Previous: Latanoprost API
• Next: Carprost Tromethamine API